Lyell Immunopharma, Inc.LYELNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +36.00% | -15.38% | +133.33% | -38.46% | -55.88% |
| Gross Profit Growth | +0.00% | +0.00% | +133.33% | -38.46% | -55.88% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +1.99% | +5.32% | +16.07% | +15.84% | +42.55% |
| Weighted Average Shares Diluted Growth | +1.99% | +5.32% | +16.07% | +15.84% | +42.55% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -22.11% | -34.55% | -38.09% | -41.08% | -34.12% |
| Book Value per Share Growth | -25.40% | -44.50% | -51.93% | -54.45% | -56.49% |
| Debt Growth | -9.38% | -6.65% | -7.66% | -8.49% | -24.40% |
| R&D Expense Growth | -1.23% | +16.94% | +0.63% | -13.42% | -28.68% |
| SG&A Expenses Growth | -24.11% | +10.29% | +4.09% | -20.15% | -9.19% |